Endocare completes $7.8 million placement:
This article was originally published in Clinica
Executive Summary
Endocare has completed a private placement of 2.2 million shares worth around $7.8 million. The company intends to use the proceeds to market existing products and to expand R&D. Endocare manufactures minimally invasive devices for the treatment of diseases of the prostate.